장골 스텐트 시장 규모, 점유율, 동향 분석 : 동맥 병변별, 최종 용도별, 유형별, 지역별 전망과 예측(2023-2030년)

The Global Iliac Stent Market size is expected to reach $1.4 billion by 2030, rising at a market growth of 5.9% CAGR during the forecast period.

North America has a significant prevalence of PAD. Therefore, the North America region captured $400.0 million revenue in the market in 2022. The incidence of PAD is predicted to climb with age and the prevalence of risk factors like diabetes and obesity rising, which will fuel the need for iliac stents as the main treatment option for revascularization and symptom relief.

PAD is a common circulatory problem in which narrowed arteries reduce blood flow to the limbs, most commonly affecting the lower extremities. It affects a large population worldwide, particularly among older adults and individuals with risk factors such as smoking, diabetes, hypertension, and dyslipidemia. Hence, the prevalence of peripheral artery disease is propelling the market's growth.

Aging is one of the major risk factors for vascular diseases such as PAD, which commonly affects the iliac arteries. As individuals age, the walls of their blood vessels may become thicker and less elastic, leading to plaque buildup and arteries narrowing. Therefore, the increasing aging population is driving the growth of the market.

However, the cost of iliac stent placement includes various components, such as the price of the stent device, hospital fees, physician fees, anesthesia costs, imaging studies, medications, and follow-up care. These expenses can add to a substantial financial burden for patients and healthcare systems, particularly in cases where multiple stents are required, or complications arise during the procedure. Thus, the high cost of treatment is hampering the market's growth.

During the height of the pandemic, many elective medical procedures, including those related to peripheral artery disease (PAD) and iliac stenting, were postponed or canceled to conserve healthcare resources and reduce the risk of viral transmission. This temporarily decreased procedural volumes and revenue for manufacturers and healthcare providers in the market. Thus, the COVID-19 pandemic had a negative impact on the market.

By Artery Lesions Analysis

On the basis of artery lesions, the market is segmented into common iliac artery lesions, severe calcified lesions, and complete obstructive lesions. The common iliac artery lesions segment recorded 60.6% revenue share in the market in 2022. Common iliac artery lesions have significant clinical implications, as they can compromise blood flow to both the internal and external iliac arteries, affecting perfusion to the pelvis, lower extremities, and vital organs.

By End-use Analysis

Based on end-use, the market is categorized into hospitals, outpatient facilities, and others. The outpatient facilities segment witnessed 26.7% revenue share in the market in 2022. Outpatient facilities offer a more comfortable and convenient environment for patients undergoing vascular interventions like iliac stent placement.

By Type Analysis

Based on type, the market is divided into self-expandable stents, balloon-expandable stents, and others. In 2022, the self-expandable stents segment garnered 62.3% revenue share in the market. Self-expandable stents are designed to be flexible and conformable, allowing for precise deployment and adaptation to the shape and curvature of the iliac arteries.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region generated 22.6% revenue share in the market in 2022. Urbanization and lifestyle changes in the Asia Pacific region have led to the adoption of Westernized lifestyles characterized by physical inactivity, unhealthy dietary habits, and increased prevalence of risk factors for cardiovascular diseases.

List of Key Companies Profiled

• Becton, Dickinson and Company
• Abbott Laboratories
• Boston Scientific Corporation
• W. L. Gore & Associates, Inc.
• Medtronic PLC
• Cook Medical, Inc.(Cook Group)
• Terumo Corporation
• iVascular S.L.U.
• Getinge AB
• Biotronik SE & Co. KG

Global Iliac Stent Market Report Segmentation

By Artery Lesions

• Common Iliac Artery Lesions
• Severe Calcified Lesions
• Complete Obstructive Lesions

By End-use

• Hospitals
• Outpatient Facilities
• Others

By Type

• Self-expandable Stents
• Balloon-expandable Stents
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

• 1.1Market Definition
• 1.2Objectives
• 1.3Market Scope
• 1.4Segmentation
  • 1.4.1Global Iliac Stent Market, by Artery Lesions
  • 1.4.2Global Iliac Stent Market, by End-use
  • 1.4.3Global Iliac Stent Market, by Type
  • 1.4.4Global Iliac Stent Market, by Geography
• 1.5Methodology for the research

Chapter 2.Market at a Glance

• 2.1Key Highlights

Chapter 3.Market Overview

• 3.1Introduction
  • 3.1.1Overview
    • 3.1.1.1Market Composition and Scenario
• 3.2Key Factors Impacting the Market
  • 3.2.1Market Drivers
  • 3.2.2Market Opportunities
  • 3.2.3Market Restraints
  • 3.2.4Market Challenges
• 3.3Porter's Five Forces Analysis

Chapter 4.Global Iliac Stent Market by Artery Lesions

• 4.1Global Common Iliac Artery Lesions Market by Region
• 4.2Global Severe Calcified Lesions Market by Region
• 4.3Global Complete Obstructive Lesions Market by Region

Chapter 5.Global Iliac Stent Market by End-use

• 5.1Global Hospitals Market by Region
• 5.2Global Outpatient Facilities Market by Region
• 5.3Global Others Market by Region

Chapter 6.Global Iliac Stent Market by Type

• 6.1Global Self-expandable Stents Market by Region
• 6.2Global Balloon-expandable Stents Market by Region
• 6.3Global Others Market by Region

Chapter 7.Global Iliac Stent Market by Region

• 7.1North America Iliac Stent Market
  • 7.1.1North America Iliac Stent Market by Artery Lesions
    • 7.1.1.1North America Common Iliac Artery Lesions Market by Country
    • 7.1.1.2North America Severe Calcified Lesions Market by Country
    • 7.1.1.3North America Complete Obstructive Lesions Market by Country
  • 7.1.2North America Iliac Stent Market by End-use
    • 7.1.2.1North America Hospitals Market by Country
    • 7.1.2.2North America Outpatient Facilities Market by Country
    • 7.1.2.3North America Others Market by Country
  • 7.1.3North America Iliac Stent Market by Type
    • 7.1.3.1North America Self-expandable Stents Market by Country
    • 7.1.3.2North America Balloon-expandable Stents Market by Country
    • 7.1.3.3North America Others Market by Country
  • 7.1.4North America Iliac Stent Market by Country
    • 7.1.4.1US Iliac Stent Market
      • 7.1.4.1.1US Iliac Stent Market by Artery Lesions
      • 7.1.4.1.2US Iliac Stent Market by End-use
      • 7.1.4.1.3US Iliac Stent Market by Type
    • 7.1.4.2Canada Iliac Stent Market
      • 7.1.4.2.1Canada Iliac Stent Market by Artery Lesions
      • 7.1.4.2.2Canada Iliac Stent Market by End-use
      • 7.1.4.2.3Canada Iliac Stent Market by Type
    • 7.1.4.3Mexico Iliac Stent Market
      • 7.1.4.3.1Mexico Iliac Stent Market by Artery Lesions
      • 7.1.4.3.2Mexico Iliac Stent Market by End-use
      • 7.1.4.3.3Mexico Iliac Stent Market by Type
    • 7.1.4.4Rest of North America Iliac Stent Market
      • 7.1.4.4.1Rest of North America Iliac Stent Market by Artery Lesions
      • 7.1.4.4.2Rest of North America Iliac Stent Market by End-use
      • 7.1.4.4.3Rest of North America Iliac Stent Market by Type
• 7.2Europe Iliac Stent Market
  • 7.2.1Europe Iliac Stent Market by Artery Lesions
    • 7.2.1.1Europe Common Iliac Artery Lesions Market by Country
    • 7.2.1.2Europe Severe Calcified Lesions Market by Country
    • 7.2.1.3Europe Complete Obstructive Lesions Market by Country
  • 7.2.2Europe Iliac Stent Market by End-use
    • 7.2.2.1Europe Hospitals Market by Country
    • 7.2.2.2Europe Outpatient Facilities Market by Country
    • 7.2.2.3Europe Others Market by Country
  • 7.2.3Europe Iliac Stent Market by Type
    • 7.2.3.1Europe Self-expandable Stents Market by Country
    • 7.2.3.2Europe Balloon-expandable Stents Market by Country
    • 7.2.3.3Europe Others Market by Country
  • 7.2.4Europe Iliac Stent Market by Country
    • 7.2.4.1Germany Iliac Stent Market
      • 7.2.4.1.1Germany Iliac Stent Market by Artery Lesions
      • 7.2.4.1.2Germany Iliac Stent Market by End-use
      • 7.2.4.1.3Germany Iliac Stent Market by Type
    • 7.2.4.2UK Iliac Stent Market
      • 7.2.4.2.1UK Iliac Stent Market by Artery Lesions
      • 7.2.4.2.2UK Iliac Stent Market by End-use
      • 7.2.4.2.3UK Iliac Stent Market by Type
    • 7.2.4.3France Iliac Stent Market
      • 7.2.4.3.1France Iliac Stent Market by Artery Lesions
      • 7.2.4.3.2France Iliac Stent Market by End-use
      • 7.2.4.3.3France Iliac Stent Market by Type
    • 7.2.4.4Russia Iliac Stent Market
      • 7.2.4.4.1Russia Iliac Stent Market by Artery Lesions
      • 7.2.4.4.2Russia Iliac Stent Market by End-use
      • 7.2.4.4.3Russia Iliac Stent Market by Type
    • 7.2.4.5Spain Iliac Stent Market
      • 7.2.4.5.1Spain Iliac Stent Market by Artery Lesions
      • 7.2.4.5.2Spain Iliac Stent Market by End-use
      • 7.2.4.5.3Spain Iliac Stent Market by Type
    • 7.2.4.6Italy Iliac Stent Market
      • 7.2.4.6.1Italy Iliac Stent Market by Artery Lesions
      • 7.2.4.6.2Italy Iliac Stent Market by End-use
      • 7.2.4.6.3Italy Iliac Stent Market by Type
    • 7.2.4.7Rest of Europe Iliac Stent Market
      • 7.2.4.7.1Rest of Europe Iliac Stent Market by Artery Lesions
      • 7.2.4.7.2Rest of Europe Iliac Stent Market by End-use
      • 7.2.4.7.3Rest of Europe Iliac Stent Market by Type
• 7.3Asia Pacific Iliac Stent Market
  • 7.3.1Asia Pacific Iliac Stent Market by Artery Lesions
    • 7.3.1.1Asia Pacific Common Iliac Artery Lesions Market by Country
    • 7.3.1.2Asia Pacific Severe Calcified Lesions Market by Country
    • 7.3.1.3Asia Pacific Complete Obstructive Lesions Market by Country
  • 7.3.2Asia Pacific Iliac Stent Market by End-use
    • 7.3.2.1Asia Pacific Hospitals Market by Country
    • 7.3.2.2Asia Pacific Outpatient Facilities Market by Country
    • 7.3.2.3Asia Pacific Others Market by Country
  • 7.3.3Asia Pacific Iliac Stent Market by Type
    • 7.3.3.1Asia Pacific Self-expandable Stents Market by Country
    • 7.3.3.2Asia Pacific Balloon-expandable Stents Market by Country
    • 7.3.3.3Asia Pacific Others Market by Country
  • 7.3.4Asia Pacific Iliac Stent Market by Country
    • 7.3.4.1China Iliac Stent Market
      • 7.3.4.1.1China Iliac Stent Market by Artery Lesions
      • 7.3.4.1.2China Iliac Stent Market by End-use
      • 7.3.4.1.3China Iliac Stent Market by Type
    • 7.3.4.2Japan Iliac Stent Market
      • 7.3.4.2.1Japan Iliac Stent Market by Artery Lesions
      • 7.3.4.2.2Japan Iliac Stent Market by End-use
      • 7.3.4.2.3Japan Iliac Stent Market by Type
    • 7.3.4.3India Iliac Stent Market
      • 7.3.4.3.1India Iliac Stent Market by Artery Lesions
      • 7.3.4.3.2India Iliac Stent Market by End-use
      • 7.3.4.3.3India Iliac Stent Market by Type
    • 7.3.4.4South Korea Iliac Stent Market
      • 7.3.4.4.1South Korea Iliac Stent Market by Artery Lesions
      • 7.3.4.4.2South Korea Iliac Stent Market by End-use
      • 7.3.4.4.3South Korea Iliac Stent Market by Type
    • 7.3.4.5Singapore Iliac Stent Market
      • 7.3.4.5.1Singapore Iliac Stent Market by Artery Lesions
      • 7.3.4.5.2Singapore Iliac Stent Market by End-use
      • 7.3.4.5.3Singapore Iliac Stent Market by Type
    • 7.3.4.6Malaysia Iliac Stent Market
      • 7.3.4.6.1Malaysia Iliac Stent Market by Artery Lesions
      • 7.3.4.6.2Malaysia Iliac Stent Market by End-use
      • 7.3.4.6.3Malaysia Iliac Stent Market by Type
    • 7.3.4.7Rest of Asia Pacific Iliac Stent Market
      • 7.3.4.7.1Rest of Asia Pacific Iliac Stent Market by Artery Lesions
      • 7.3.4.7.2Rest of Asia Pacific Iliac Stent Market by End-use
      • 7.3.4.7.3Rest of Asia Pacific Iliac Stent Market by Type
• 7.4LAMEA Iliac Stent Market
  • 7.4.1LAMEA Iliac Stent Market by Artery Lesions
    • 7.4.1.1LAMEA Common Iliac Artery Lesions Market by Country
    • 7.4.1.2LAMEA Severe Calcified Lesions Market by Country
    • 7.4.1.3LAMEA Complete Obstructive Lesions Market by Country
  • 7.4.2LAMEA Iliac Stent Market by End-use
    • 7.4.2.1LAMEA Hospitals Market by Country
    • 7.4.2.2LAMEA Outpatient Facilities Market by Country
    • 7.4.2.3LAMEA Others Market by Country
  • 7.4.3LAMEA Iliac Stent Market by Type
    • 7.4.3.1LAMEA Self-expandable Stents Market by Country
    • 7.4.3.2LAMEA Balloon-expandable Stents Market by Country
    • 7.4.3.3LAMEA Others Market by Country
  • 7.4.4LAMEA Iliac Stent Market by Country
    • 7.4.4.1Brazil Iliac Stent Market
      • 7.4.4.1.1Brazil Iliac Stent Market by Artery Lesions
      • 7.4.4.1.2Brazil Iliac Stent Market by End-use
      • 7.4.4.1.3Brazil Iliac Stent Market by Type
    • 7.4.4.2Argentina Iliac Stent Market
      • 7.4.4.2.1Argentina Iliac Stent Market by Artery Lesions
      • 7.4.4.2.2Argentina Iliac Stent Market by End-use
      • 7.4.4.2.3Argentina Iliac Stent Market by Type
    • 7.4.4.3UAE Iliac Stent Market
      • 7.4.4.3.1UAE Iliac Stent Market by Artery Lesions
      • 7.4.4.3.2UAE Iliac Stent Market by End-use
      • 7.4.4.3.3UAE Iliac Stent Market by Type
    • 7.4.4.4Saudi Arabia Iliac Stent Market
      • 7.4.4.4.1Saudi Arabia Iliac Stent Market by Artery Lesions
      • 7.4.4.4.2Saudi Arabia Iliac Stent Market by End-use
      • 7.4.4.4.3Saudi Arabia Iliac Stent Market by Type
    • 7.4.4.5South Africa Iliac Stent Market
      • 7.4.4.5.1South Africa Iliac Stent Market by Artery Lesions
      • 7.4.4.5.2South Africa Iliac Stent Market by End-use
      • 7.4.4.5.3South Africa Iliac Stent Market by Type
    • 7.4.4.6Nigeria Iliac Stent Market
      • 7.4.4.6.1Nigeria Iliac Stent Market by Artery Lesions
      • 7.4.4.6.2Nigeria Iliac Stent Market by End-use
      • 7.4.4.6.3Nigeria Iliac Stent Market by Type
    • 7.4.4.7Rest of LAMEA Iliac Stent Market
      • 7.4.4.7.1Rest of LAMEA Iliac Stent Market by Artery Lesions
      • 7.4.4.7.2Rest of LAMEA Iliac Stent Market by End-use
      • 7.4.4.7.3Rest of LAMEA Iliac Stent Market by Type

Chapter 8.Company Profiles

• 8.1Becton, Dickinson, and Company
  • 8.1.1Company Overview
  • 8.1.2Financial Analysis
  • 8.1.3Segmental and Regional Analysis
  • 8.1.4Research & Development Expense
  • 8.1.5Recent strategies and developments:
    • 8.1.5.1Trials and Approvals:
  • 8.1.6SWOT Analysis
• 8.2Abbott Laboratories
  • 8.2.1Company Overview
  • 8.2.2Financial Analysis
  • 8.2.3Segmental and Regional Analysis
  • 8.2.4Research & Development Expense
  • 8.2.5SWOT Analysis
• 8.3Boston Scientific Corporation
  • 8.3.1Company Overview
  • 8.3.2Financial Analysis
  • 8.3.3Segmental and Regional Analysis
  • 8.3.4Research & Development Expense
  • 8.3.5Recent strategies and developments:
    • 8.3.5.1Trials and Approvals:
  • 8.3.6SWOT Analysis
• 8.4W. L. Gore & Associates, Inc.
  • 8.4.1Company Overview
  • 8.4.2SWOT Analysis
• 8.5Medtronic PLC
  • 8.5.1Company overview
  • 8.5.2Financial Analysis
  • 8.5.3Segmental and Regional Analysis
  • 8.5.4Research & Development Expenses
  • 8.5.5Recent strategies and developments:
    • 8.5.5.1Trials and Approvals:
  • 8.5.6SWOT Analysis
• 8.6Cook Medical, Inc. (Cook Group)
  • 8.6.1Company Overview
  • 8.6.2SWOT Analysis
• 8.7Terumo Corporation
  • 8.7.1Company Overview
  • 8.7.2Financial Analysis
  • 8.7.3Segmental and Regional Analysis
  • 8.7.4Research & Development Expenses
  • 8.7.5Recent strategies and developments:
    • 8.7.5.1Trials and Approvals:
    • 8.7.5.2Product Launches and Product Expansions:
  • 8.7.6SWOT Analysis
• 8.8iVascular S.L.U.
  • 8.8.1Company Overview
  • 8.8.2SWOT Analysis
• 8.9Getinge AB
  • 8.9.1Company Overview
  • 8.9.2Financial Analysis
  • 8.9.3Segmental and Regional Analysis
  • 8.9.4Research & Development Expense
  • 8.9.5Recent strategies and developments:
    • 8.9.5.1Trials and Approvals:
  • 8.9.6SWOT Analysis
• 8.10.Biotronik SE & Co. KG
  • 8.10.1Company Overview
  • 8.10.2SWOT Analysis

Chapter 9.Winning Imperatives of Iliac Stent Market